Project Grant R43HL182336
Award Date 9/15/25
Completion Date 8/31/26
Dollars Obligated $500K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90502, USA
Similar Awards
- This Project Grant award, totaling $499,585.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The University of Texas Health Science Center at Tyler. The project aims to develop a novel therapeutic strategy called "Two-Target Fibrinolytic Therapy" (T2FT) to increase the efficacy of empyema treatment. The research involves preclinical testing and optimization of a combination therapy using alteplase (ALT), a docking site...
- This Project Grant award of $944,676 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a novel platelet-inspired nanotechnology called Synthoplate (SP) by Haima Therapeutics LLC. The goal is to restore hemostasis, or normal blood clotting function, in patients on antiplatelet agents like clopidogrel and ticagrelor who suffer from traumatic brain injuries. This is a critical unmet need, as...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,998,124 Cooperative Agreement under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University (Stanford University) for a Phase 2 clinical trial studying the use of elafin (tiprelestat) as a treatment for pulmonary arterial hypertension (PAH). The award supports a 3-arm, randomized, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of daily subcutaneous elafin...
- This federal Project Grant award of $552,413.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to Thomas Jefferson University's Sidney Kimmel Medical College. The grant will support research over a period of 4 years, from April 1, 2025 to January 31, 2029, with the goal of investigating siRNA-mediated in vivo knockdown of key regulators of platelet and megakaryocyte function, including the P2Y12 receptor,...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $249,000.00 to Oakland University to conduct research on the pre-mRNA processing and function of alternatively spliced isoforms of Tissue Factor Pathway Inhibitor (TFPI), a vital factor in the balance of hemostasis between pro- and anticoagulant factors. The research aims to differentiate the physiological, site-specific production of each TFPI isoform...
- This federal Project Grant award of $542,442.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support the development and testing of a new molecular sensor, named MCATS (Mechano-Assisted CAS12A Tension Sensor), that can detect the mechanical forces generated by human platelets. This technology aims to provide rapid and accurate diagnosis of Heparin-Induced Thrombocytopenia (HIT), which is a serious condition affecting a small percentage of...
- This $306,656 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on approaches to enable large-scale biomanufacturing of heparin, a critical anticoagulant medication. The award was granted to Bioparin, LLC on February 1, 2025, with a planned completion date of January 31, 2026. The project aims to develop alternative, reliable modern drug production processes for heparin,...
- This $936,858 Cooperative Agreement award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will fund a Phase 2 clinical trial to evaluate the safety and efficacy of the drug tiprelestat (recombinant human elafin) for the treatment of pulmonary arterial hypertension (PAH). The clinical trial, known as the ATHENA trial, will be a multi-center, randomized, double-blind, placebo-controlled study to assess the impact of tiprelestat on pulmonary...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $511,135 to the University of California, Los Angeles (UCLA) for research on the structure and biology of Tissue Factor Pathway Inhibitor-2 (TFPI-2). The key objectives of this award are to: 1) delineate the specific residues and segments of the TFPI-2 Kunitz Domain 1 (KD1) that confer protease specificity for plasmin, Factor XIa, and...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...